0.00Open0.00Pre Close0 Volume0 Open Interest40.00Strike Price0.00Turnover160.12%IV14.22%PremiumSep 20, 2024Expiry Date0.00Intrinsic Value100Multiplier33DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.4907Delta0.0235Gamma7.00Leverage Ratio-0.1038Theta0.0111Rho3.44Eff Leverage0.0422Vega
Neurogene Stock Discussion
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...
No comment yet